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Abstract: Interstitial lung disease (ILD) and lung fibrosis are characterized by different grades 
of fibrosis and inflammation. Persistent low-grade inflammation is believed to play a major 
pathogenic role, leading to an imbalance of cytokines, growth factors, and tissue proteinases. 
Recruited monocytes and macrophages play a pivotal role through their cytokine expression 
and possibly differentiation into fibrocytes, pericytes, or myofibroblasts. Atypical bacterial 
infections can cause ILD, although not usually in the form of usual interstitial pneumonia. On 
the other hand, bacterial colonization is frequently encountered in patients with chronic fibrotic 
lung disorders, and patients regularly undergo antibacterial treatment. As demonstrated in 
patients with diffuse panbronchiolitis and other chronic respiratory disorders, treatment with 
macrolides can be beneficial. This is partly explained by their antimicrobial effects but, for 
macrolides, immunomodulatory properties have been identified which might also be beneficial 
in patients with ILD or lung fibrosis. This article reviews the immunology of lung fibrogenesis 
and putative implications of macrolides for reinstallation of tolerance.
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Introduction
Interstitial lung diseases (ILD) are a heterogeneous group of diffuse parenchyma 
  disorders characterized by different grades of fibrosis and inflammation. Despite 
  varying pathogenesis, they are grouped together because of their similar clinical 
  presentation, chest radiographic appearance, histology, and physiological features.1,2
Environmental, infectious, or self antigens provoke inflammation which, due to 
either ongoing antigen exposure or lack of resolution, results in fibrosis. Environmental 
triggers include silica, metals, and hard metal/organic dust exposure, fungi, or animal 
proteins. Fungal infections, atypical bacterial pneumonias, or viral pneumonias can 
result in ILD, occurring predominantly in immunocompromised hosts. Drug-induced 
pneumopathy due to methotrexate or bleomycin therapy can also cause ILD.
Primary ILD is defined as the absence of underlying disease, whilst immunological 
diseases, such as systemic sclerosis, systemic lupus erythematosus, or rheumatoid arthri-
tis, are generally responsible for secondary disease.3 Idiopathic interstitial   pneumonias 
comprise seven different entities according to their clinical,   radiological, and pathological 
presentation.1 Of these, idiopathic pulmonary fibrosis, which   corresponds with the histo-
pathological finding of usual interstitial pneumonia, is the prototype of fibrosing ILD.
Connective tissue diseases, hypersensitivity pneumonitis, and asbestosis can also 
lead to usual interstitial pneumonia, where abnormal proliferation of mesenchymal 
cells, especially the occurrence of fibrotic foci, leads to a reticular alteration of Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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lung parenchyma, described as honeycombing.4 However, 
  nonspecific interstitial pneumopathy, which is more typical 
for secondary ILD, shows a diffuse histopathological picture 
and generally a more inflammatory, cell-rich infiltrate.5,6
Patients with ILD and lung fibrosis are susceptible to 
bacterial superinfection. This is due to primary or iatrogenic 
immunosuppression, reduced mucus clearance, bacterial 
colonization, or biofilm production. Patients regularly require 
antibiotic treatment. Long-term treatment strategies similar to 
those used for cystic fibrosis are rare in ILD, with the excep-
tion of chronic aspergillus or nontuberculous mycobacterial 
infection.7 Antibiotics serve to reduce the bacterial load and 
virulence, and also, notably for macrolides, have additional 
beneficial properties. Azithromycin, clarithromycin, and 
erythromycin also reduce bacterial adherence and biofilm 
production, and have an immunomodulatory effect.8 These 
agents can potentially reinstall tolerance on the one hand 
and protect the patient from ongoing danger signals and 
damage produced by bacterial colonization or infections on 
the other. Indeed, positive effects of macrolides have been 
reported, eg, in patient cohorts with diffuse panbronchiolitis.9 
However, the question of whether macrolide treatment is 
beneficial in ILD or lung fibrosis in general, is elusive. This 
review gives an overview of the immunology in ILD and the 
possible implications of the immunomodulatory effects of 
macrolide antibiotics.
Role of inflammation
According to our current understanding of lung fibrosis, an 
injury or “danger signal” leads to parenchymal damage and 
subsequently triggers lung fibrosis.10 Initial inflammation 
in the form of alveolitis occurs in all forms of ILD, although 
there is often less inflammation in usual interstitial   pneumonia 
than in nonspecific interstitial pneumopathy (Wells AU, 
personal communication). Why inflammation turns into 
  autoinflammation in these patients is unclear. The likely 
answer is that the normal resolution of inflammation is altered 
and that tolerance towards the host lung parenchyma is lost. 
In any case, inflammatory cells induce a Th-1/2   imbalance in 
favor of profibrotic Th-2 cytokines, such as interleukin (IL)-4 
or IL-13, which are regarded as key drivers of fibrosis.11,12 
IL-17 produced by Th17+ T cell subsets has been identified as 
a further orchestrator of the inflammatory cascade and fibrosis 
in interstitial lung disease.13,14 Once damage has occurred, 
immune cells of different lineages are activated (Figure 1). 
Alveolar macrophages, basophils,   lymphocytes, and mast 
cells are described in the   inflammatory infiltrate, often with 
a perivascular distribution.15,16 How they are orchestrated 
in detail and their effects on stromal cells is not completely 
understood.
Macrophages and monocytes, as members of the innate 
immune system, produce both proinflammatory and profi-
brotic cytokines.17 Monocytes patrolling on the endothelium 
are recruited by certain stimuli, such as infection, and then 
differentiate into macrophages or dendritic cells.18 Our 
research group has found that monocytes of patients with 
systemic sclerosis express significantly more tissue inhibi-
tors of   metalloproteinases than healthy controls (Huigens 
et al, submitted for publication). In contrast with neutro-
phils, monocytes persist in the lung parenchyma for up to 
two months without persistent influx of blood monocytes.19 
  Macrophages also promote fibroblast proliferation and colla-
gen deposition.2 Whether monocytes solely express cytokines 
or differentiate into direct profibrotic cells, such as fibro-
cytes, pericytes, or myofibroblasts, has not been completely 
  clarified, but it has been reported that, like mesenchymal stem 
cells, monocytes do have plurigenic properties.20
Mast cells belong to the innate immune system. They are 
regarded as “tissue sensors” and are also involved in ILD. 
Mast cell activation can be IgE-mediated or occur directly 
via antigens or stimulation of Toll-like receptors.21 Mast cell 
degranulation has been observed in ILD in several studies.22 
Mast cell vesicles contain various profibrotic factors, such as 
IL-4 and transforming growth factor beta (TGF-β), and mast 
cells also produce metalloproteinases.23 Our group has recently 
shown that degranulating mast cells are the main source of 
TGF-β in the skin of patients with systemic sclerosis.24 Their 
proximity to fibroblasts and blood vessels may facilitate 
fibrogenesis. TGF-β is of paramount importance in fibrotic 
lung disease and also a differentiation factor for Th17 cells.25 
Gene expression profiles of ILD lung samples demonstrated a 
TGF-β fingerprint.26 Similar to parasitic or allergic inflamma-
tion, mast cells, as well as basophils, are likely to be involved 
in producing a Th2-immune response in lung fibrosis.21,27
Lymphocytes belong to the adaptive immune system. They 
are regularly encountered in the inflammatory infiltrate in ILD 
samples and play an important role by their cytokine produc-
tion and capacity to trigger (auto) antigen-specific immunity. 
Both T cells and B cells are recruited, whereby T effector cells 
support plasma cells to produce   autoantibodies. T cells also 
downregulate the inflammatory process. It has been shown in 
bacterial infection that T regulatory cells express IL-10 which 
protects the   tissue from “friendly fire” by reducing cellular 
interferon-γ expression.28Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Fibrocytes
Fibrocytes are circulating, bone marrow-derived CD14+ 
cells which can produce collagen.29,30 They have features 
of both monocytes and stromal cells. In wound healing, 
they differentiate into myofibroblasts, yet remain able to 
present antigen to lymphocytes.31 In animal models of lung 
fibrosis, circulating fibrocytes are recruited to injured lungs 
as an integral component of the pathogenesis of pulmonary 
fibrosis.32 In patients with systemic sclerosis, there are more 
fibrocytes in the circulation, expressing higher levels of IL-10 
upon proinflammatory stimulation compared with healthy 
individuals.33 The concept of fibrocytes being involved 
in ILD is appealing because these cells are derived from an 
inexhaustible source, the bone marrow, and thus can replenish 
fibrotic effector cells in the tissue.
Epithelial-mesenchymal transition
Despite inflammation still being regarded as essential for 
fibrogenesis, there is convincing evidence that inflammation 
and fibrosis can be dissociated. Ongoing epithelial injury 
and activation can lead to a transdifferentiation of epithelial 
cells into mesenchymal cells, a process known as epithelial–
mesenchymal transition, which occurs when epithelial cells 
lose cell–cell attachment, undergo cytoskeletal remodeling, 
and finally obtain a mesenchymal phenotype. This process is 
considered to be a key factor for fibrogenesis in general, and 
epithelial–mesenchymal transition indeed has been observed 
in ILD.34,35 Induction of epithelial–mesenchymal transition 
in alveolar epithelial cells is initiated by several factors, 
notably TGF-β, which certainly is a main stimulatory factor 
for epithelial–mesenchymal transition in ILD.34,36 However, 
several other factors, such as fibroblast growth factor, and 
also endothelin-1 and reactive oxygen species, can be respon-
sible for epithelial–mesenchymal transition.34
Reactive oxygen species
Free radical reactions contribute to fibrogenesis. The source 
of these free radicals is typically inflammatory stimuli.37 
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Figure 1 Transition of inflammation to fibrosis in interstitial lung disease. Toxic or infectious antigens delivered via air or blood supply to lung parenchyma represent a 
danger signal which triggers an inflammatory response. First, the innate immune system is activated, eg, via mast cells which degranulate and release chemoattractants and 
growth factors, such as TGF-β. Myofibroblasts which differentiate from fibroblasts, pericytes, or fibrocytes, serve as key effector cells in fibrosis by producing collagen and 
alpha-smooth muscle actin. They are also derived from epithelial cells by eMT. Lymphocytes recognize antigens which are presented by macrophages. They express mainly 
Th-2 cytokines, proliferate, and trigger autoimmunity. Proliferative vasculopathy is a result of ongoing low-grade inflammation, and insufficient vascular blood supply further 
promotes fibrosis.
Abbreviations:  eMT,  epithelial–mesenchymal  transition;  IL,  interleukin;  TGF,  transforming  growth  factor;  ROS,  reactive  oxygen  species;  MMP,  metalloproteinases; 
TIMP-1, tissue inhibitor of metalloproteinases-1; TNF, tumor necrosis factor.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Regardless of the cause, tissue damage leads to oxidative 
stress.38 In lung inflammation, an increased oxygen burden 
mainly arises from the accumulation of inflammatory cells, 
including macrophages and neutrophils, which show an 
exaggerated release of oxygen radicals.39 Nitric oxide spe-
cies increase fibroblast proliferation.40 Increased expression 
of nitric oxide species has been described in unclassified 
pulmonary fibrosis, and expression of nitric oxide species has 
been detected also during experimental granuloma formation 
in vitro and in granulomatous inflammation caused by silica, 
zymosan, and dextran beads in vivo.41–43
Influence of infection  
on fibrogenesis
According to current consensus, usual interstitial pneumo-
nia in its classical presentation is generally not caused by 
infection. Notwithstanding, atypical pneumonias can lead 
to fibrosing ILD, with a picture similar to cryptogenic orga-
nizing pneumonitis.1 In a recent case series, four patients 
with pulmonary histoplasmosis developed ILD, all of them 
showing different forms of inflammation. One had bron-
chocentric granulomatosis, one had pulmonary alveolar 
proteinosis, one had diffuse alveolar damage, and, in one 
biopsy, the clinical manifestations suggested tuberculous 
primo-infection with systemic dissemination.44 In another 
study of patients with tuberculosis, atypical mycobacterial 
infections, or sarcoidosis, it was demonstrated that alpha-
smooth muscle actin as a marker of fibrosis, is expressed 
around both necrotic and non-necrotic granulomas. 
Alpha-smooth muscle actin expression was higher in the 
granulomas of patients with mycobacterial infection than 
in those with sarcoidosis.45 This shows that the etiology 
of inflammation is important for fibrogenesis, rather than 
inflammation per se, and it is more likely that ILD occurs 
in individuals with a genetic predisposition.46 These indi-
viduals are more likely to develop autoinflammation and, 
in some cases, also autoimmunity with identified (self) 
antigens. One can argue that in certain patients suffering 
from atypical pneumonia, antibiotic treatment, eg, with 
macrolides or quinolones, may prevent autoinflammation 
or autoimmunity.
It remains unclear whether bacterial superinfection 
ILD directly triggers fibrosis in individuals with under-
lying ILD. However, cystic fibrosis demonstrates that 
infections do   accelerate deterioration of lung fibrosis, and 
antibiotic   treatment or prophylaxis reduces mortality in these 
patients.
Macrolide therapy
Macrolides, such as erythromycin, clarithromycin, and 
azithromycin, are antibiotic compounds which are effective 
against Gram-positive and Gram-negative bacteria,   including 
streptococci, Haemophilus influenzae, staphylococci, 
  mycoplasma, mycobacteria, rickettsia, and chlamydia. Apart 
from their established antibacterial effects, there is growing 
evidence for anti-inflammatory properties of macrolides in 
chronic respiratory diseases, such as diffuse panbronchiolitis, 
asthma, cystic fibrosis, or chronic bronchitis.8,9 Macrolides 
share a macrocyclic lactone ring with other immunosup-
pressive substances, such as rapamycin.47 Their antimicro-
bial and possibly immunosuppressive effect is exerted by 
binding to the 50S ribosomes of prokaryotic and eukaryotic 
organisms, affecting protein synthesis.48 Interestingly, the 
immunomodulatory effect is limited to macrolides which 
share a 14-member ring, and the dose required for immuno-
modulation is lower compared with the dose necessary for 
antimicrobial activity. In patients with cystic fibrosis, long-
term treatment with azithromycin achieved a better forced 
expiratory volume in one second and fewer exacerbations 
than placebo.49 Apart from the simple killing of bacteria, this 
effect seems to be supported by reducing bacterial adherence, 
inhibiting biofilm formation, and decreasing microbiological 
virulence.50
Macrolides not only accumulate in bacteria, but also in 
host leukocytes.47 They have an inhibitory effect on proin-
flammatory cytokines, such as tumor necrosis factor-α, IL-1, 
and nitric oxide. In contrast, macrolides increase the expres-
sion of IL-10, one of the most important anti-inflammatory 
cytokines produced by T or B regulatory cells.51 IL-10 
is central in protecting host tissue during an infection by 
inhibiting the synthesis of interferon gamma by both T cells 
and natural killer cells and the synthesis of nitric oxide by 
macrophages (Figure 2).52
The exact mechanism by which cellular cytokines are 
either upregulated or downregulated by macrolides is not 
clear. It seems that suppression of nuclear factor-κB and 
an increase in cyclic adenosine monophosphate levels are 
involved.8,53 Another important observation is that macrolides 
accelerate apoptosis of neutrophils and other leukocytes and 
the removal of cell debris by macrophages, respectively.54 
Proapoptotic effects has also been postulated for improve-
ment of mucosa-associated lymphoid tissue tumors under 
long-term macrolide therapy.55 Macrolide treatment has also 
been shown to reduce superoxide and elastase release from 
human leukocytes.56Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Positive effects of macrolides have been achieved 
in patients with cryptogenic organizing pneumonia and 
  radiation-related ILD. However, these effects have only been 
observed in small case studies, and need to be confirmed in 
controlled trials.
Conclusion
Lung fibrogenesis is a heterogenic complex process associ-
ated with destruction of lung parenchyma. Inflammation and 
cytokine imbalance are pivotal elements in the development 
of lung fibrosis. Although infection does not cause usual 
interstitial pneumonia, bacteria can trigger ILD and prob-
ably contribute secondarily to the progression of idiopathic 
interstitial pneumonias in general. Macrolides are safe and 
effective against a broad range of bacteria, some of which are 
responsible for ILD. Apart from their antimicrobial effects, 
macrolides also have immunomodulatory properties. These 
might protect individuals from ILD progression by interfer-
ing with cytokine production, oxygen stress reduction, and 
host-pathogen interactions. Chronic low-dose macrolide 
therapy has been successful in patients suffering from dif-
fuse panbronchiolitis and other chronic inflammatory airway 
diseases, including ILD or lung fibrosis, but there are no 
randomized, placebo-controlled trials available. All   clinical 
and in vitro observations therefore need   confirmation in 
clinical trials.
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